AIM: To estimate the point prevalence of pulmonary hypertension (PH) and determine the associated factors for PH in patients with systemic lupus erythematosus (SLE). METHODS: A prospective cross-sectional study of 114 patients with SLE was conducted in a single tertiary center. Transthoracic echocardiography was performed to estimate the pulmonary arterial pressures. PH was defined as resting systolic pulmonary artery pressure (sPAP) ≥ 40 mmHg, in the absence of left heart disease. RESULTS: PH was identified in nine patients (7.9%) who had few cardiopulmonary symptoms. SLE patients with PH had higher SLE disease activity index score. In particular, serum uric acid (UA) was significantly higher in patients with PH than in those without PH. In multivariate analysis, UA remained significant for the presence of PH. Moreover, serum UA level correlated significantly with plasma NT-pro-B-type natriuretic peptide level as well as sPAP. At the cutoff level of 6.5 mg/dL, serum UA had reasonable accuracy for predicting the presence of PH in SLE patients (sensitivity 66.7% and specificity 96.2%). CONCLUSION: A significant number of SLE patients in rheumatology practice have undiagnosed PH with few discernible symptoms. Serum UA level may be useful as a surrogate marker for screening of PH in patients with SLE.
AIM: To estimate the point prevalence of pulmonary hypertension (PH) and determine the associated factors for PH in patients with systemic lupus erythematosus (SLE). METHODS: A prospective cross-sectional study of 114 patients with SLE was conducted in a single tertiary center. Transthoracic echocardiography was performed to estimate the pulmonary arterial pressures. PH was defined as resting systolic pulmonary artery pressure (sPAP) ≥ 40 mmHg, in the absence of left heart disease. RESULTS: PH was identified in nine patients (7.9%) who had few cardiopulmonary symptoms. SLEpatients with PH had higher SLE disease activity index score. In particular, serum uric acid (UA) was significantly higher in patients with PH than in those without PH. In multivariate analysis, UA remained significant for the presence of PH. Moreover, serum UA level correlated significantly with plasma NT-pro-B-type natriuretic peptide level as well as sPAP. At the cutoff level of 6.5 mg/dL, serum UA had reasonable accuracy for predicting the presence of PH in SLEpatients (sensitivity 66.7% and specificity 96.2%). CONCLUSION: A significant number of SLEpatients in rheumatology practice have undiagnosed PH with few discernible symptoms. Serum UA level may be useful as a surrogate marker for screening of PH in patients with SLE.
Authors: C Reátegui-Sokolova; Manuel F Ugarte-Gil; Rocío V Gamboa-Cárdenas; Francisco Zevallos; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Mariela Medina; Zoila Rodriguez-Bellido; Cesar A Pastor-Asurza; Graciela S Alarcón; Risto A Perich-Campos Journal: Clin Rheumatol Date: 2017-01-18 Impact factor: 2.980
Authors: Hong Ki Min; Jae Ho Lee; Seung Min Jung; Jennifer Lee; Kwi Young Kang; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park Journal: Korean J Intern Med Date: 2015-02-27 Impact factor: 2.884
Authors: Claudia Elera-Fitzcarrald; Cristina Reátegui-Sokolova; Rocio Violeta Gamboa-Cardenas; Mariela Medina; Francisco Zevallos; Victor Román Pimentel-Quiroz; Jorge Mariano Cucho-Venegas; José Alfaro-Lozano; Zoila Rodriguez-Bellido; Cesar Augusto Pastor-Asurza; Risto Alfredo Perich-Campos; Graciela S Alarcón; Manuel Francisco Ugarte-Gil Journal: Lupus Sci Med Date: 2020-02-05